康哲药业签独家协议推出痛风新药ABP-671

财中社12-02

财中社12月2日电康哲药业（00867）发布公告，宣布其全资附属公司与杭州新元素药业有限公司签订了关于治疗痛风及高尿酸血症的1类新药ABP-671的独家商业化协议。根据协议，公司获得了该产品在中国大陆、香港特别行政区及澳门特别行政区的独家商业化权利，合作期限为十年，且在特定条件下可自动续期十年。ABP-671是一种用于治疗痛风及高尿酸血症的创新药物，目前正在进行2b/3期临床试验。初步数据显示，该...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488379673?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-02 19:46","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2488379673","market":"hk","top_or_hot":-1,"title":"康哲药业签独家协议 推出痛风新药ABP-671","media":"财中社","content":"<div>\n<p>财中社12月2日电康哲药业（00867）发布公告，宣布其全资附属公司与杭州新元素药业有限公司签订了关于治疗痛风及高尿酸血症的1类新药ABP-671的独家商业化协议。根据协议，公司获得了该产品在中国大陆、香港特别行政区及澳门特别行政区的独家商业化权利，合作期限为十年，且在特定条件下可自动续期十年。ABP-671是一种用于治疗痛风及高尿酸血症的创新药物，目前正在进行2b/3期临床试验。初步数据显示，该...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202195816abefa8fc&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业签独家协议 推出痛风新药ABP-671</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业签独家协议 推出痛风新药ABP-671\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-02 19:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202195816abefa8fc&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>财中社12月2日电康哲药业（00867）发布公告，宣布其全资附属公司与杭州新元素药业有限公司签订了关于治疗痛风及高尿酸血症的1类新药ABP-671的独家商业化协议。根据协议，公司获得了该产品在中国大陆、香港特别行政区及澳门特别行政区的独家商业化权利，合作期限为十年，且在特定条件下可自动续期十年。ABP-671是一种用于治疗痛风及高尿酸血症的创新药物，目前正在进行2b/3期临床试验。初步数据显示，该...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202195816abefa8fc&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202195816abefa8fc&s=b","article_id":"2488379673","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202195816abefa8fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2488379673","pubTimestamp":1733139960,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"财中社12月2日电康哲药业 发布公告，宣布其全资附属公司与杭州新元素药业有限公司签订了关于治疗痛风及高尿酸血症的1类新药ABP-671的独家商业化协议。ABP-671是一种用于治疗痛风及高尿酸血症的创新药物，目前正在进行2b/3期临床试验。公司预期该产品如获批上市，将对其业绩产生积极影响，满足临床对高效安全药物的需求。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1593":"医美概念股","BK1191":"制药","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","00867":"康哲药业","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC"},"translate_title":"CMS signs exclusive agreement to launch new gout drug ABP-671","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1},"content_text":"财中社12月2日电康哲药业（00867）发布公告，宣布其全资附属公司与杭州新元素药业有限公司签订了关于治疗痛风及高尿酸血症的1类新药ABP-671的独家商业化协议。根据协议，公司获得了该产品在中国大陆、香港特别行政区及澳门特别行政区的独家商业化权利，合作期限为十年，且在特定条件下可自动续期十年。ABP-671是一种用于治疗痛风及高尿酸血症的创新药物，目前正在进行2b/3期临床试验。初步数据显示，该产品在多个剂量组表现出良好的药效和安全性，有望为患者提供更有效、安全的治疗选择。根据《2021中国高尿酸及痛风趋势白皮书》，中国高尿酸血症的患病率为13.3%，患者人数约1.77亿，痛风发病率为1.1%，患者人数约1466万，显示出市场对高效安全降尿酸药物的迫切需求。此次合作将使公司的产品矩阵更加多元化，特别是在风湿免疫科和内分泌科的市场资源方面具有协同效应。公司预期该产品如获批上市，将对其业绩产生积极影响，满足临床对高效安全药物的需求。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488379673"}

康哲药业签独家协议 推出痛风新药ABP-671

精彩评论

康哲药业签独家协议推出痛风新药ABP-671